Jeffrey Smith, Ph.D.

Head of Preclinical and Toxicology
Viatris
Morgantown, West Virginia

Jeff received his Ph.D. in Pharmacology and Toxicology from West Virginia University School of Medicine.  He currently serves as the Head of Preclinical and Toxicology for Viatris.

Presentation(s):

• P-039 - (Poster #39) Efficacy and safety of MR-107A-02 (novel fast-acting meloxicam formulation) for the treatment of acute moderate-to-severe pain following bunionectomy

  Thursday, September 4, 2025
  4:00 PM - 5:30 PM PST

• P-038 - (Poster #38) Efficacy and safety of MR-107A-02 (novel meloxicam fast-acting formulation) for the treatment of acute moderate-to-severe pain following herniorrhaphy

  Thursday, September 4, 2025
  4:00 PM - 5:30 PM PST

• P-040 - (Poster #40) Opioid sparing effect of MR-107A-02 (novel fast-acting meloxicam formulation) for the treatment of acute moderate-to-severe pain following bunionectomy and herniorrhaphy

  Thursday, September 4, 2025
  4:00 PM - 5:30 PM PST

• P-041 - (Poster #41) Pharmacokinetics study comparing MR-107A-02 (novel fast-acting meloxicam formulation) 15mg tablet with meloxicam (Mobic®) 15mg in healthy adult male subjects

  Thursday, September 4, 2025
  4:00 PM - 5:30 PM PST